Literature DB >> 30103245

Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features.

Anna Guadall1, Elodie Lesteven1, Gil Letort1, Sarah Awan Toor1, Marc Delord2, Doriane Pognant1, Mégane Brusson3, Emmanuelle Verger1,4, Nabih Maslah1,4, Stéphane Giraudier1,4,5, Jerome Larghero6, Valerie Vanneaux6, Christine Chomienne1,4,5, Wassim El Nemer3, Bruno Cassinat1,4, Jean-Jacques Kiladjian1,5,7.   

Abstract

Thromboembolic events are the main cause of mortality in BCR-ABL1-negative myeloproliferative neoplasms (MPNs) but their underlying mechanisms are largely unrecognized. The Janus kinase 2 (JAK2)V617F mutation is the most frequent genetic alteration leading to MPN. Usually found in haematopoietic progenitors and stem cells, this mutation has also been described in endothelial cells (ECs) of MPN patients. In this study, we have questioned the impact of the JAK2V617F mutation on EC phenotype and functions. We developed an induced pluripotent stem cells strategy to compare JAK2 mutant and wild-type ECs. Transcriptomic assays showed that several genes and pathways involved in inflammation, cell adhesion and thrombotic events were over-represented in JAK2V617F ECs and expression levels of von Willebrand factor and P-selectin (CD62P) proteins were increased. Finally, we found that leucocytes from MPN patients adhere more tightly to JAK2V617F ECs. Our results show that JAK2V617F ECs have a pro-inflammatory and pro-thrombotic phenotype and were functionally pro-adherent. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30103245     DOI: 10.1055/s-0038-1667015

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

1.  New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches.

Authors:  Michal Bar-Natan; Ronald Hoffman
Journal:  Haematologica       Date:  2019-01       Impact factor: 9.941

2.  From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Authors:  Brady L Stein; Karlyn Martin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.

Authors:  Alexandre Guy; Johanne Poisson; Chloe James
Journal:  Leukemia       Date:  2021-03-03       Impact factor: 11.528

4.  Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms.

Authors:  Anish V Sharda; Thomas Bogue; Alexandra Barr; Lourdes M Mendez; Robert Flaumenhaft; Jeffrey I Zwicker
Journal:  Clin Cancer Res       Date:  2021-08-16       Impact factor: 13.801

5.  Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms.

Authors:  Loula Papageorgiou; Ismail Elalamy; Patrick Vandreden; Grigoris T Gerotziafas
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

Review 6.  Megakaryocytes as the Regulator of the Hematopoietic Vascular Niche.

Authors:  Huichun Zhan; Kenneth Kaushansky
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

7.  Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.

Authors:  Radhika Gangaraju; Jihyun Song; Soo Jin Kim; Tsewang Tashi; Brandi N Reeves; Krishna M Sundar; Perumal Thiagarajan; Josef T Prchal
Journal:  Blood Adv       Date:  2020-03-24

Review 8.  Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.

Authors:  Alison R Moliterno; Yelena Z Ginzburg; Ronald Hoffman
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113

Review 9.  Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.

Authors:  Brandi N Reeves; Joan D Beckman
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 4.213

Review 10.  Emerging Factors Implicated in Fibrotic Organ-Associated Thrombosis: The Case of Two Organs.

Authors:  Orly Leiva; Roelof H Bekendam; Brenda D Garcia; Cristal Thompson; Alan Cantor; Vipul Chitalia; Katya Ravid
Journal:  TH Open       Date:  2019-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.